Home » Market News » DirectorsTalk Highlights » Sativa Investments’ comments on The Advisory Council on the Misuse of Drugs finding “evidence of medicinal benefit” of some cannabis products
Sativa Investments plc

Sativa Investments’ comments on The Advisory Council on the Misuse of Drugs finding “evidence of medicinal benefit” of some cannabis products

The prospect of GPs prescribing medicinal cannabis moved a step closer yesterday according to The Times after the official body that advises the government on drugs backed the move.

The Advisory Council on the Misuse of Drugs said there was “evidence of medicinal benefit” of some cannabis products for some conditions and recommended that they should be able to be prescribed as long as they met appropriate safety standards.

Geremy Thomas, founder and CEO of Sativa Investments, the UK’s first medicinal cannabis investment vehicle, said: “Sativa is pleased to see that the facts of cannabis having medicinal benefits to patients are now being recognised by the UK authorities, along with suggestions to the home secretary to move the product to a Schedule 2 drug, allowing patients to be treated with medicinal cannabis.

“There are already a number instances where the exception has been made to allow the use of medicinal cannabis for patients, now it’s time make it available for everyone who suffer from symptoms that the product can treat.”

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.